Document is current
Any future updates will be listed below
-
Authors
Barba, Lorenzo
Gaetani, Lorenzo
Sperandei, Silvia
Di Sabatino, Elena
Abu-Rumeileh, Samir
Halbgebauer, Steffen
Oeckl, Patrick
Steinacker, Petra
Parnetti, Lucilla
Di FIlippo, Massimiliano
Otto, Markus https://orcid.org/0000-0003-4273-4267
-
Funding
Funding for this research was provided by:
Martin Luther-University Halle-Wittenberg (JCS24/02, CS22/06)
Ministero della Salute (RF-2021-12373319)
Fondazione Italiana Sclerosi Multipla (2023/PR-Single/017)
Bundesministerium für Bildung und Forschung (FTLDc 01GI1007A)
EU Moodmarker progam (01EW2008)
Martin-Luther-Universität Halle-Wittenberg
- License Information
-
More Information
Article History
Received: 17 September 2024
Revised: 2 December 2024
Accepted: 3 December 2024
First Online: 21 December 2024
Declarations
:
: LG participated on advisory boards for, and received writing honoraria and travel grants from Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. MDF participated on advisory boards and steering committees for and received speaker or writing honoraria, research support and funding for travelling from Alexion, BMS, Bayer, Biogen Idec, Genzyme, Horizon, Janssen, Merck, Mylan, Novartis, Roche, Siemens Healthineers, Teva, and Viatris. MO received consulting fees from Biogen, Axon, Roche, and Grifols and participated on the Biogen ATLAS trial board, all unrelated to the present study. PO, SH, and MO are co-inventors of a patent application for using beta-synuclein measurement in blood (EP4014048A1, US2022283184A1).
